Immuneering Corporation, a clinical-stage oncology company, has announced that it will present initial phase 1 pharmacokinetic, pharmacodynamic modeling, and safety data for its universal-RAS program IMM-1-104 at the American Association for Cancer Research Annual Meeting 2023. The data presentation will take place during a virtual investor event to be held concurrently with the conference on April 18, 2023, at 9:00 a.m. ET.
The company’s lead product candidate is IMM-1-104, which is currently in phase 1/2A clinical trials in advanced solid tumor patients harboring RAS mutations. The aim of the program is to develop a universal-RAS therapy that achieves broad activity through deep cyclic inhibition of the MAPK pathway that impacts cancer cells while sparing healthy cells.
Also Read:
Immuneering’s development pipeline also includes a universal-MAPK program called IMM-6-415, in addition to several early-stage programs. The company is working towards creating better medicines for cancer patients and to advance its pipeline further.
The presentation will be made available to the public via a live webcast, while the event will be archived for 90 days in the Investor Relations section of Immuneering’s website at Events & Presentations. Participants can register for the call using a provided link, and anyone is welcome to attend. Immuneering’s management will provide an overview of the program, including new data from its ongoing study.
Also Read:
According to John Reynders, President and CEO of Immuneering, the company is excited to share the initial phase 1 pharmacokinetic, pharmacodynamic and safety data for its universal-RAS program at the American Association for Cancer Research Annual Meeting 2023. He further stated that the company is committed to developing better treatment options for cancer patients, and the data presentation is a significant milestone in its journey to achieve the goal.
The company’s goal is to develop medicines for broad populations of cancer patients, and IMM-1-104 is a promising candidate in this endeavor. The program’s deep cyclic inhibition of the MAPK pathway has the potential to be a universal therapy for any cancer patient with RAS mutations. The presentation will provide insight into the drug’s safety and efficacy, and the positive results will be encouraging for patients and the oncology community.
Also Read:
In conclusion, the data presentation on the universal-RAS program IMM-1-104 during the American Association for Cancer Research Annual Meeting 2023 is a crucial milestone for Immuneering in developing better medicines for cancer patients. The company’s commitment to advancing its pipeline and diversifying its portfolio is admirable, and it will be interesting to see the presentation’s outcome. The positive results will be significant for cancer patients with RAS mutations, and it may pave the way for new and improved cancer treatments.
In Other News Around the World: